Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Syndax Pharmaceuticals IncSNDX · Entity 4578 | Director | May 17, 2017 | May 19, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Syndax Pharmaceuticals Inc
Report date May 17, 2017 · Filed May 19, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.58 · Expires 2027-05-17 | Direct | 5,000 |
Reported balance
After 2017-05-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-17 · Grant · Acquired 5,000 · Balance 5,000 F1: 1/48th of the shares subject to the option shall vest monthly over a four-year period. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option shall vest monthly over a four-year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 17, 2017 Filed May 19, 2017 15:27 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Options (Right to buy) · Derivative | 5,000 | $0.00 Strike: $13.58 | $0.00 |
DisclosureSEC source: 0001562180-17-002010 · primarydocument.xml · derivative · entry 1 Sledge George W. Jr. · CIK 0001601351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-05-17 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 21:25 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $11.81 | $0.00 |
DisclosureSEC source: 0001562180-16-003357 · primarydocument.xml · derivative · entry 1 Sledge George W. Jr. · CIK 0001601351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2026-10-31 F1 · derivative.exercise_date: One hundred percent (100%) of the total number of shares underlying the option shall vest on October 31, 2017, subject to the reporting person's continuous service through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.